Oncoscience · 2015 · 10 citations · 4 references
Life SciencesImmunologyPharmacologyCancer ImmunologyImmunopharmacologyInnate ImmunityCytokine BiologyInnate Immune ModulationInnate Immune Signaling PathwaysNatural Killer Cell BiologyNatural Killer Cell FunctionNatural Killer Cell RegulationInhibitory Killer Cell Immunoglobulin-like ReceptorsInnate Immune Signaling ModulationJak Inhibitor TherapyJak InhibitorsJak-stat Pathway AntagonismJak-stat Signaling In ImmunityJak-stat Signaling PathwayNatural Killer Cell Inhibitory Signaling
NK cells are innate immune effector cells recognizing and killing virus-infected or malignant cells [1].NK cell function is tightly regulated by a complex balance between various activating and inhibitory NK cell receptors. In addition, several cytokines (IL-2, IL-12, IL-15 and IL-18) mediated via the JAK/STAT pathway are critical for NK cell development and activation. Thus it is tempting to speculate that the novel class of immune-modulatory compounds (i.e. the JAK inhibitors) are able to modify NK cell biology in vitro and in vivo. We recently support this idea by demonstrating that the first approved JAK1/2/(3) inhibitor ruxolitinib dramatically impacts NK cell biology in vivo in patients suffering from myeleloproliferative neoplasia (MPN)[2]. Ruxolitinib-treated MPN patients have drastically reduced
4
Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease
Silvia Spoerl, Nimitha R. Mathew, Michael Bscheider et al. · Blood · 2014 · 394 citations
JAK Inhibition Impairs NK Cell Function in Myeloproliferative Neoplasms
Kathrin Schönberg, Janna Rudolph, Maria Vonnahme et al. · Cancer Research · 2015 · 179 citations